Загрузка...
Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
Radium-223-dichloride ((223)RaCl(2)) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of (223)RaCl(2) at 4 week...
Сохранить в:
| Опубликовано в: : | Diagnostics (Basel) |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665607/ https://ncbi.nlm.nih.gov/pubmed/26854158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics5030358 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|